Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.60 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.51 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30969281 | 0.91 | PARP10 (0.57) | PARP10SAE1UBA2NPC1SMN1; SMN2 | |
| SCHEMBL6309831 | 0.89 | PARP10 (0.62) | PARP10SAE1UBA2PLK1NPC1 | |
| SCHEMBL30969328 | 0.88 | TP53 (0.56) | PARP10SAE1UBA2TSHR | |
| SCHEMBL30969225 | 0.86 | TSHR (0.65) | MAPK1USP2ALOX15TSHRHSD17B10 | |
| SCHEMBL30969240 | 0.85 | KDM4E (0.57) | PARP10NPC1SMN1; SMN2DRD2DRD4 | |
| SCHEMBL30969268 | 0.84 | MAPT (0.70) | PLK1NPC1SMN1; SMN2RAB9AMAPK1 | |
| SCHEMBL1715450 | 0.84 | PRSS1 (0.64) | PARP10DRD3 | |
| SCHEMBL606438 | 0.83 | PARP10 (0.72) | PARP10SAE1UBA2PLK1SMN1; SMN2 | |
| SCHEMBL1086686 | 0.83 | PARP10 (0.72) | PARP10SAE1UBA2NPC1SMN1; SMN2 | |
| SCHEMBL13715503 | 0.82 | PARP10 (0.62) | PARP10PLK1NPC1MAPK1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282498-B2 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION (US) | 2007-10-16 | — | — | US | claimed |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2005-03-17 | — | — | US | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| EP-1326831-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2003-07-16 | — | — | EP | claimed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2002-09-12 | — | — | US | claimed |
| WO-2002020480-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
| EP-4642766-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024145585-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20090023737-A1 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands | NEUROGEN CORPORATION (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080167324-A1 | Thiazolymethyl and Oxazolylmethyl Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| US-20040220253-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| US-6743817-B2 | AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR BRAIN RECEPTORS; ANXIOLYTICS, ANTIDEPRESSANTS, TREATING SLEEP AND PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2004-06-01 | — | — | US | disclosed |
| US-6653471-B2 | Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction | NEUROGEN CORPORATION | 2003-11-25 | — | — | US | disclosed |
| EP-1339681-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020151718-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002046155-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | PARP10 4135/4885SAE1 4562/4885UBA2 3209/4885 |
| US-20040220253-A1 | Synthesis of pyrrole amides | GABRA5, GABRA2, GABRA1 | PARP10 2145/4885SAE1 3504/4885UBA2 2252/4885 |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NPSR1, GABRE, CHRNE | PARP10 1202/4885SAE1 4312/4885UBA2 2512/4885 |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | HTR1A, GABRA1, GABRE | PARP10 1434/4885SAE1 3883/4885UBA2 2178/4885 |
| US-20020151718-A1 | Synthesis of pyrrole amides | GABRA5, GABRA2, GABRA1 | PARP10 2145/4885SAE1 3504/4885UBA2 2252/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | PARP10 4135/4885SAE1 4562/4885UBA2 3209/4885 |
| US-20090023737-A1 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands | GABRA4, GABRA2, GABRA5 | PARP10 3257/4885SAE1 4237/4885UBA2 2957/4885 |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | GABRA3, GABRA1, GABBR1 | PARP10 2987/4885SAE1 4706/4885UBA2 4184/4885 |
| US-20080167324-A1 | Thiazolymethyl and Oxazolylmethyl Heteroaryl Derivatives | GABBR1, GABBR2, GABRA3 | PARP10 4722/4885SAE1 4753/4885UBA2 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.